Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection

Cell Death and Disease

Volumn 7, Issue 3, 2016, Pages

  Agrati, C ^a   Castilletti, C ^a   Casetti, R ^a   Sacchi, A ^a   Falasca, L ^a   Turchi, F ^a   Tumino, N ^a   Bordoni, V ^a   Cimini, E ^a   Viola, D ^a   Lalle, E ^a   Bordi, L ^a   Lanini, S ^a   Martini, F ^a   Nicastri, E ^a   Petrosillo, N ^a   Puro, V ^a   Piacentini, M ^a   Di Caro, A ^a   Kobinger, G P ^b   Zumla, A ^c   Ippolito, G ^a   Capobianchi, M R ^a   more..

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; CD38 ANTIGEN; FAS ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; ZMAPP;

ADULT; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; AUTOPHAGY; CASE REPORT; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; DRUG MEGADOSE; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS REACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTIGENS, CD95; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HEMORRHAGIC FEVER, EBOLA; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84979505705     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.55     Document Type: Article

References (37)

1. Sanchez A, Geisbert T, Feldmann H. Filoviridae: Marburg and Ebola Viruses. Wolters kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2009.
2. WHO Ebola situation reports. Available at: apps who int/ebola/en/current377 situation/ebolasituation-report 2015 (accessed on 22 July 2015).
3. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C et al. Ebola RNA persistence in Semen of Ebola virus disease survivors - preliminary report. N Engl J Med 2015.
4. Howlett P, Brown C, Helderman T, Brooks T, Lisk D, Deen G et al. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg Infect Dis 2016;22:150-152.
5. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK et al. Persistence of Ebola Virus in ocular fluid during convalescence. N Engl J Med 2015;372:2423-2427.
6. Wise J. Scottish Ebola nurse is readmitted to isolation unit in London. BMJ 2015;351:h5426.
7. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, Garrison A et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 2007;196:S296-S304.
8. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347-2370.
9. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4:e837.
10. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-426.
11. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 2015;112:4719-4724.
12. Falasca L, Agrati C, Petrosillo N, Di Caro A, Capobianchi MR, Ippolito G et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ 2015;22:1250-1259.
13. Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014;10:781-790.
14. Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun 2014;55:1-9.
15. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128:163-168.
16. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007;196:S357-S363.
17. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999;179:S188-S191.
18. Petrosillo N, Nicastri E, Lanini S, Capobianchi MR, Di Caro A, Antonini M et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis 2015;15:432.
19. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-684.
20. Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011;5:e1275.
21. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load and nitric oxide levels. J Virol 2004;78:10370-10377.
22. Mandl JN, Feinberg MB. Robust and sustained immune activation in human Ebola virus infection. Proc Natl Acad Sci USA 2015;112:4518-4519.
23. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, De Heer G, Kluge S et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014;371:2394-2401.
24. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005;79:14189-14196.
25. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175:1184-1191.
26. Gupta M, Mahanty S, Greer P, Towner JS, Shieh WJ, Zaki SR et al. Persistent infection with ebola virus under conditions of partial immunity. J Virol 2004;78:958-967.
27. Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 2010;202:681-689.
28. Simone R, Piatti G, Saverino D. The inhibitory co-receptors: a way to save from anergy the HIV-specific T cells. Curr HIV Res 2009;7:266-272.
29. Audet J, Kobinger GP. Immune evasion in ebolavirus infections. Viral Immunol 2015;28:10-18.
30. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000;97:12289-12294.
31. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009;29:511-520.
32. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188:1630-1638.
33. Gupta M, Spiropoulou C, Rollin PE. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 2007;364:45-54.
34. Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant 2013;13:1-8.
35. Petrara MR, Freguja R, Gianesin K, Zanchetta M, De RA. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol 2013;4:311.
36. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:2402-2409.
37. Di Caro A, Puro V, Fusco FM, Capobianchi MR, Lanini S, Lauria FN et al. The added value of vlong-lasting preparedness for the management of a patient with Ebola. Eur J Intern Med 2015; pii: S0953-6205 00078-3.